UPDATE 1-AbbVie raises full-year profit forecast as Humira fuels quarterly sales [Reuters]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Reuters
By Reuters Staff 2 Min Read (Reuters) -AbbVie Inc on Friday beat estimates for quarterly revenue and profit and raised its 2021 earnings forecast, helped by demand for its rheumatoid arthritis drug in the United States where it is yet to face competition from cut-price copies. AbbVie’s beat-and-raise quarter come after several rival drugmakers such as Eli Lilly, Merck & Co Inc and Bristol Myers Squibb missed estimates for first-quarter earnings. Sales for AbbVie’s rheumatoid arthritis drug Humira in the first quarter rose 3.5% to $4.87 billion, beating expectations of $4.78 billion. Revenue, however, fell 8.3% in markets outside the United States due to rising competition, especially in Europe. Shares of the North Chicago, Illinois-based company climbed 2.1% in premarket trading after AbbVie’s revenue was also lifted by recovering demand for Botox, the blockbuster anti-wrinkle injection it gained through its $63 billion deal for Allergan. Demand for the anti-wrinkle injection, which
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis [Yahoo! Finance]Yahoo! Finance
- Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisPR Newswire
- Big Growth Ahead: Biologic Drugs Market to Hit $823.4 Billion by 2028, Reveals BCC Research [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/2/24 - Beat
ABBV
Sec Filings
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ABBV's page on the SEC website